Immediate Impact
7 from Science/Nature 79 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
Works of Edward M. Chan being referenced
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
2023
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
2014 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Edward M. Chan | 1016 | 810 | 186 | 396 | 43 | 1.4k | |
| Damien M. Cronier | 1069 | 1019 | 91 | 274 | 35 | 1.5k | |
| Remy B. Verheijen | 618 | 772 | 211 | 519 | 50 | 1.3k | |
| Brett E. Houk | 590 | 701 | 143 | 933 | 47 | 1.6k | |
| N. Schleucher | 789 | 601 | 160 | 591 | 32 | 1.6k | |
| Maja J.A. de Jonge | 826 | 416 | 71 | 852 | 40 | 1.6k | |
| Pamela Drullinsky | 598 | 466 | 121 | 515 | 57 | 1.3k | |
| Giuliana Cavalloni | 694 | 367 | 331 | 497 | 49 | 1.6k | |
| Avi I. Einzig | 1190 | 405 | 133 | 380 | 34 | 1.6k | |
| Wendy Walsh | 629 | 305 | 138 | 600 | 29 | 1.4k | |
| Jean Powers | 545 | 372 | 127 | 548 | 32 | 1.3k |
All Works
Login with ORCID to disown or claim papers
Loading papers...